Velocity-Based Resistance Training Effects on Inflammation in Older Adults
4 maj 2026 uppdaterad av: National Taipei University
Dose-Response Effects of Velocity-Based Resistance Training on Anti-Inflammatory Responses in Older Adults
This study aims to investigate the effects of resistance training (RT) with different training volumes on immune modulation and anti-inflammatory responses in older adults.
Participants will be randomly assigned to one of three RT volume groups (low, medium, or high) or a non-exercise control group.
Participants in the training groups will complete a 4-week RT program, followed by a 4-week detraining phase.
The findings are expected to provide evidence for volume-specific RT prescriptions to support healthy aging.
Studieöversikt
Status
Rekrytering
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Beräknad)
60
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Shun-Hsi Tsai, Ph.D.
- Telefonnummer: 68523 +88686741111
- E-post: shunhsi@mail.ntpu.edu.tw
Studieorter
-
-
-
Taipei, Taiwan, 116
- Rekrytering
- National Taiwan Normal University
-
Kontakt:
- Hung-Wen Liu, Ph.D.
- Telefonnummer: +88677496863
- E-post: hwliu@ntnu.edu.tw
-
Kontakt:
- Kuan-Tsen Yeh, M.S.
- Telefonnummer: +886932815383
- E-post: mickyyehyeh@gmail.com
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Ja
Beskrivning
Inclusion Criteria:
- Aged 60-75 years or older
- No regular resistance training habit (defined as ≥2 sessions per week) in the past year
- No musculoskeletal injuries within the past six months
Exclusion Criteria:
- Obesity (BMI > 30 kg/m²), diabetes, hypertension, cancer, heart, kidney, or liver disease, or any other condition that may influence study outcomes.
- Regular use of anti-inflammatory medications (e.g., NSAIDs).
- Smoking or alcohol abuse
- Inability to safely perform the prescribed resistance exercise movements
- Unable to fully comprehend the study information and instructions.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: low training volume resistance exercise
Participants assigned to the low-volume resistance training group will perform one set per exercise at a load corresponding to 80% of 1RM.
Each set will be terminated when movement velocity decreases by 30% from the first repetition.
Rest intervals of 2-3 minutes will be provided between exercises.
|
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions.
All sessions will be supervised by research personnel to ensure proper technique and safety.
Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
|
|
Experimentell: medium training volume resistance exercise
Participants assigned to the medium-volume resistance training group will perform three sets per exercise at 80% of 1RM.
Each set will be terminated when movement velocity decreases by 30% relative to the first repetition.
Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises.
|
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions.
All sessions will be supervised by research personnel to ensure proper technique and safety.
Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
|
|
Experimentell: high training volume resistance exercise
Participants assigned to the high-volume resistance training group will perform five sets per exercise at 80% of 1RM.
Each set will be terminated when movement velocity decreases by 30% relative to the first repetition.
Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises.
|
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions.
All sessions will be supervised by research personnel to ensure proper technique and safety.
Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
|
|
Inget ingripande: sedentary control
Participants in control trial stayed sedentary during the period.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Changes in IL-6 concentration
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Plasma IL-6 concentrations will be measured and reported in pg/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in soluble IL-6 receptor concentration
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Soluble IL-6 receptor concentrations will be measured and reported in ng/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in soluble gp130 concentration
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Soluble gp130 concentrations will be measured and reported in ng/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in IL-10 concentration
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
IL-10 concentrations will be measured and reported in pg/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in IL-1RA concentration
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
IL-1RA concentrations will be measured and reported in pg/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in TNF-α concentration
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
TNF-α concentrations will be measured and reported in pg/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Borgs Ratings of Perceived Exertion (RPE)
Tidsram: 1-hour during each exercise intervention
|
Borgs RPE is a method of estimating exertion rating, based on a 1 to 10 rating scale (1 being the no exertion at all, 10 being maximal exertion).
|
1-hour during each exercise intervention
|
|
Handgrip strength
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Maximal handgrip strength will be assessed using a digital hand dynamometer and reported in kilograms.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Knee extension strength
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Maximal voluntary isometric and isokinetic concentric knee extension strength of the dominant leg will be assessed using an isokinetic dynamometer and reported in Newton-meters.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
30-second chair-stand test
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Lower-body functional capacity will be assessed by the number of repetitions completed during a 30-second chair-stand test.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Single-leg balance test
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Balance performance will be assessed as the duration of single-leg stance and reported in seconds.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Timed up and go test
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Functional mobility will be assessed using the Timed Up and Go test, with performance quantified as the time (seconds) required to stand up from a seated position, walk 3 meters, turn, walk back, and sit down.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in SHIP1 protein expression in peripheral blood mononuclear cells (PBMCs)
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular SHIP1 protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in gp130 (CD130) protein expression in PBMCs
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular gp130 (CD130) protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in STAT3 protein expression in PBMCs
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular STAT3 protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in phosphorylated STAT3 protein expression in PBMCs
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular phosphorylated STAT3 (p-STAT3) protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in IL-6 receptor alpha (CD126) protein expression in PBMCs
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular IL-6 receptor alpha (CD126) protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in Beta-2 adrenergic receptor (β2-AR) protein expression in PBMCs
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular β2-adrenergic receptor (β2-AR) protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in SOCS3 protein expression in PBMCs
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular SOCS3 protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in white blood cell count
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Total white blood cell count will be measured and reported in cells/μL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in lymphocyte count
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Lymphocyte count will be measured and reported in cells/μL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in neutrophil count
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Neutrophil count will be measured and reported in cells/μL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in monocyte count
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Monocyte count will be measured and reported in cells/μL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Body fat percentage
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Body fat percentage will be measured using a body composition analyzer and reported as a percentage.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Lean body mass
Tidsram: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Total lean body mass will be measured using a body composition analyzer and reported in kilograms.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Shun-Hsi Tsai, Ph.D., National Taipei University
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
20 april 2026
Primärt slutförande (Beräknad)
1 mars 2029
Avslutad studie (Beräknad)
1 december 2029
Studieregistreringsdatum
Först inskickad
15 april 2026
Först inskickad som uppfyllde QC-kriterierna
28 april 2026
Första postat (Faktisk)
5 maj 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
8 maj 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
4 maj 2026
Senast verifierad
1 april 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- ECKIRB1140803
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .